NCT06301438Recruiting
Dalpiciclib in HR+/HER2- ABC
Efficacy and Safety of Dalpiciclib in HR+/HER2- Advanced Breast Cancer: a Real-world Study
Source: ClinicalTrials.gov · Last updated 3 Feb 2026
Brief summary (registry, in English)
To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 103 (estimated)
- First submitted
- 2 Mar 2024
- Start date
- May 2024
- Primary completion date
- Jan 2027
- Lead sponsor
- RenJi Hospital
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06301438
What you commit to
- Study type: Observational
- Planned participants: 103
- From May 2024 to the primary completion date, Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of immunodeficiency
Other
- Pregnant or breastfeeding
Who the study is looking for
- Histologically confirmed advanced breast cancer
- Hormone receptor-positive and human epidermal growth factor receptor 2-negative
- ECOG 0-1
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Renji Hospital, School of Medicine, Shanghai Jiaotong University Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.